Tuesday, December 1 | 3:00 p.m. to 4:00 p.m. | T7-SSBR06-7 | Room N227B
Here, attendees will learn how preoperative MRI helps in women with low-risk, screen-detected ductal carcinoma in situ (DCIS).
As trials increasingly support active monitoring as an alternative to surgery for DCIS, choosing the right patients depends on accurately judging disease extent and ruling out hidden invasive cancer.
Rachel Kaplan-Reeves, MD, from Weill Cornell Radiology, will share her team’s findings. The study identified consecutive women at a single institution who were diagnosed with screen-detected DCIS on stereotactic-guided biopsy between 2012 and 2024.
The analysis included 97 patients with 109 DCIS lesions. The median age was 54, and 43% met high-risk screening criteria. MRI enhanced visualization for 71% of the lesions.
MRI showed a greater extent of disease than mammography in 38% of cases and a similar extent in 28%. MRI prompted additional biopsies in 35% of patients, with a malignant yield of 28%. It changed the extent of disease in 17% of patients and upstaged disease in 2%. At surgery, 14% of patients were upgraded to invasive cancer.
MRI may help refine risk stratification for women considering active surveillance, particularly those whose disease extent or invasive component may not be captured by mammography alone, the authors reiterated.
Find out more by attending this presentation.
